Corporate Governance :: Oncolytics Biotech, Inc. (ONCY)

Director	Audit	Compensation	Governance	Science and Technology
Wayne Pisano View Bio	Audit Committee	Compensation Committee	Governance Committee	Science and Technology Committee
Deborah M. Brown, B.Sc., M.B.A. View Bio	Audit Committee	Compensation Committee	Governance Committee	Science and Technology Committee
Angela Holtham, MBA, FCMA, FCPA, ICD.D View Bio	Audit Committee	Compensation Committee	Governance Committee	Science and Technology Committee
William G. Rice, PhD View Bio	Audit Committee	Compensation Committee	Governance Committee	Science and Technology Committee
Bernd R. Seizinger, MD, PhD View Bio	Audit Committee	Compensation Committee	Governance Committee	Science and Technology Committee
Matt Coffey, PhD, MBA View Bio	Audit Committee	Compensation Committee	Governance Committee	Science and Technology Committee
	Audit Committee	Compensation Committee	Governance Committee	Science and Technology Committee

Wayne Pisano

Chair

Mr. Pisano has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He is currently the president and CEO of VaxInnate a privately held biotech company. He joined Immunovaccine's Board in October 2011 with a depth of experience across the spectrum of commercial operations, public immunization policies and pipeline development. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He is credited with driving Sanofi Pasteur's leadership within the worldwide influenza market and capturing 50 percent of global sales. He also laid the foundation for the company's global pediatric vaccines strategy. He joined Sanofi Pasteur in 1997, assuming increasing levels of responsibility. He was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. During his tenure as CEO, Mr. Pisano bolstered the Sanofi Pasteur pipeline with the acquisitions of Acambis PLC, a bio-tech based in Boston in 2008 and Shantha Biotechnics, a highly regarded Indian vaccine company in 2010. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.

Deborah M. Brown, B.Sc., M.B.A.

Director

In addition to being a Management Consultant since 2014, Ms. Brown is currently a Managing Partner at Accelera Canada, a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. Ms. Brown holds an MBA from University of Western Ontario's Ivey School of Business, an Hons B.Sc. from the University of Guelph and completed the Merck executive development programme at the University of Hong Kong, INSEAD and Northwestern University's Kellogg School of Management.

Angela Holtham, MBA, FCMA, FCPA, ICD.D

Director

Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation (ICD.D).

William G. Rice, PhD

Director

Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He has also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University and was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan Medical Center.

Bernd R. Seizinger, MD, PhD

Director

Dr. Seizinger has held the position of Chairman/Executive Chairman of Opsona Therapeutics Ltd. since 2009. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Selzinger held professorships and senior staff appointments at Harvard Medical School, Princeton University and Massachusetts General Hospital.

Matt Coffey, PhD, MBA

President and Chief Executive Officer

A co-founder of the Company, Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey has held the positions of Chief Operating Officer of the Company since December 2008, Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.

Name	View Document
Board of Directors Mandate	Download Board of Directors Mandate
Code of Ethics for CEO, CFO and Accounting Officers	Download Code of Ethics for CEO, CFO and Accounting Officers
Employee Code of Ethics	Download Employee Code of Ethics
Corporate Trading Policy	Download Corporate Trading Policy
Policy on Trading and Confidential Information	Download Policy on Trading and Confidential Information
Policy Regarding Accounting and Auditing Matters	Download Policy Regarding Accounting and Auditing Matters
Audit Committee Mandate	Download Audit Committee Mandate
Compensation Committee Mandate	Download Compensation Committee Mandate
Governance Committee Mandate	Download Governance Committee Mandate
Science and Technology Committee Mandate	Download Science and Technology Committee Mandate

Corporate Governance

Board Members & Committees

Governance Documents